icon-account icon-glass


prozac withdrawal success video


Have you tried to Come Off Prozac only to reinstate due to the Prozac Withdrawal Symptoms?  Have you even tried to do a slow Prozac Taper yet still could not come off Prozac?  The Royal College of Psychiatrists have warned that coming off antidepressant can cause symptoms lasting for months and that doses should be gradually lowered over months. Our nonprofit has helped people in 78 countries to Get Off Prozac and because many members of our team has been through withdrawals we know how to help ease Prozac Withdrawal and make a Prozac Taper more comfortable.  We know what herbs, drugs or over-the-counter interact with Prozac and we want you to feel better as you go through a gentle Prozac Taper. Please do not attempt to Taper Prozac on your own, contact our nonprofit and let our expert team help you with our in-home taper program. CONTACT us for a FREE consultation.*


how it


Our Prozac In-Home weaning program is a slow taper that allows you to safely step down from Prozac under the guidance of Our Team, Your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean  Prozac until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help ease Prozac withdrawal and support wellbeing*

Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Prozac Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; goals; and interactions. Don't Wean Prozac alone, work with our Prescription Drug Experts.*

Imagine being Free of Prozac Dependency 

- Proven Withdrawal Program completed In-Home with Expert Guidance

- Slowly Taper Prozac

- All-Natural Nutraceuticals to help Ease Prozac Withdrawal*

- Professional Information on Interactions

- Free Mentoring on our 24/7 Private Discussion Board

- Free Assessment Upon Starting our Program (a $400 value)

 Enter Discount Code top of page for FREE Ground Shipping on your Withdrawal Program  *USA & Canada Only



Is it Your Time to Start a New Journey?


Betty - Prozac Taper Success Story

I Thank you Point of Return for all of your patience and kindness.  We in a fragile state need your extra kindness.  Thank you for all you have done for me and my roach to recovery. more...              

Betty (Prozac Withdrawal Success Story)

Eric - prozac weaning success

I also need to thank the whole Point of Return staff.  I called many times looking for help and always got an uplifting word or laugh. For those currently struggling, try their withdrawal  program. Give the Point of Return team a call or email.  more...

Eric (Prozac Withdrawal Success Story)

Rachel - Paxil Withdrawal Success Story

I have found that if you work the Point of Return program that it will work for you.  The results are there if you do your part and work the program. I strongly recommend Point of Return to others. more...

Rachel (Prozac Withdrawal Success Story)

 For me this withdrawal program was an obsession…I followed it closely. It worked a miracle in my life! This program is the best out there it covers everything. I am FREE of Prozac and I got my TESTIMONY back! Thank you from the bottom of my heart! 

—Kelly (Prozac Withdrawal Success Story)

                               using a Natural Approach

Our team has survived psychoactive drug withdrawal. More...

  We have helped people in 78 countries and in every state of the USA. More...

We have extensive media coverage; television, print, radio. More...


Message sent, thanks! Will get back to your shortly.







      Prozac targets Serotonin, the neurotransmitter found primarily in the gastrointestinal tract, blood platelets and central nervous system, and is thought to contribute to feelings of happiness.

      Prozac has the longest half-life of any antidepressant, meaning it stays in the body for an extended period of time. Many patients do not realize they are in withdrawal as the symptoms may appear weeks after stopping the drug. A gradual taper is recommended yet many still find the symptoms too challenging and need assistance.

      Prozac (Fluoxetine) failed in clinical trials as an antihypertensive medication and again as an obesity drug. While it did not show improvement for patients hospitalized as psychotic and actually made some patients worse, Prozac found its home as an antidepressant after it improved the mood of five mildly depressed volunteers. It was then launched as an antidepressant in 1988 and was responsible for more than one-quarter of Eli Lilly Pharmaceutical's income. The marketing strategy of providing a cure for an illness was born by Interbrand, the world's leading branding company (Microsoft, Nikon, Nintendo, Sony) and the name Prozac was chosen because it was short and had a positive and professional sound. Lilly printed 8 million brochures highlighting the symptoms of depression with a treatment option and patients began asking for the drug by name. It was the success of Prozac that created the market with similar antidepressants called SSRIs (Selective Serotonin-Reuptake Inhibitors).

      Now Prozac is being marketed to our dogs under the trade name Reconcile to curb the anxiety from being left alone for long periods of time. The studies used to obtain approval for the drug stated that 30% of animals were found to have 'phobias' or 'fears', while 12% were found to have 'separation-related problems' when parted with their owner.

      Eli Lilly, the U.S. manufacture, said: 'Treatment for companion animals is a relatively new area for us.' The UK recently approved Prozac for use in pets. Side effects of Reconcile include lethargy, reduced appetite, vomiting, shaking, diarrhea, restlessness, excessive barking, aggression and seizures.

      top of page



      shaking, confusion, dizziness, sweating, severe headache, insomnia, anxiety, burning or tingling sensations around the body, brain zaps / brain shivers, vertigo, lightheadedness, rushing noise in the head, agitation, negative, tearful, concentration problem, tremors, diarrhea, vomiting, reduced appetite, nightmares, excessive dreaming, gastrointestinal issues

       Double-blind controlled studies indicate that 35-78% of patients after five weeks or more of treatment who abruptly stop antidepressants or titrate in 10mg increments or more, will develop one of more of the discontinuation symptoms that can range from mild-moderate discomfort to extremely distressing. The duration of symptoms can vary in time between individuals and can include the following symptoms:

      Dizziness, Vertigo, Lightheadedness, Lightheadedness, Difficulty walking, Nausea / vomiting, Fatigue, Headaches, Insomnia, Shock-like sensations, Parathesia (skin crawling, burning or prickling), Visual disturbances, Muscle pain, chills


      abnormal dreams, abnormal ejaculation, abnormal vision, anxiety, diminished sex drive, dizziness, dry mouth, flu-like symptoms, flushing, gas, headache, impotence, insomnia, itching, loss of appetite, nausea, nervousness, rash, sinusitis, sleepiness, sore throat, sweating, tremors, upset stomach, vomiting, weakness, yawning, abnormal taste, agitation, bleeding problems, chills, confusion, ear pain, emotional instability, fever, frequent urination, high blood pressure, increased appetite, loss of memory, palpitations, ringing in the ears, sleep disorders, weight gain


      Severe: visual impairment, tardive dyskinesia, suicidal ideation, arrhythmia exacerbation, heart failure, myocardial infarction, proteinuria, seizures, peptic ulcer, hematemesis, GI bleeding, pancreatitis, cholecystitis, esophageal ulceration, GI obstruction, muscle paralysis, pulmonary hypertension, thrombosis, ventricular fibrillation, coronary vasospasm, stroke, atrial fibrillation, cardiac arrest, bradycardia, pneumothorax, apnea, pulmonary edema, laryngeal edema, ocular hypertension, hearing loss, oliguria, diabetic ketoacidosis, hyperkalemia, torticollis, thrombotic thrombocytopenic purpura (TTP, aplastic anemia, hemolytic anemia, SIADH, torsade de pointes, ventricular tachycardia, erythema nodosum, pulmonary fibrosis, lupus-like symptoms, bronchospasm, erythema multiforme, exfoliative dermatitis, Stevens-Johnson syndrome, anaphylactoid reactions, angioedema, serum sickness, vasculitis,Drug Reaction with Eosinophilia and  Systemic Symptoms (DRESS), laryngospasm, toxic epidermal necrolysis, eosinophilic pneumonia, pulmonary embolism, optic neuritis, hepatic failure, hepatic necrosis, renal failure (unspecified), bone fractures, serotonin syndrome, persistent pulmonary hypertension of the newborn, neonatal abstinence syndrome 

      Moderate: impotence (erectile dysfunction), ejaculation dysfunction, constipation, oral ulceration, melena, esophagitis, cholelithiasis, dysphagia, glossitis, gastritis, colitis, stomatitis, neuropathic pain, myoclonia, teeth grinding (bruxism), migraine, akathisia, ataxia, hypertonia, hostility, psychosis, euphoria, depression, anemia, hypotension, angina, orthostatic hypotension, peripheral edema, edema, vaginal bleeding, atopic dermatitis, skin ulcer, photophobia, conjunctivitis, elevated hepatic enzymes, urinary incontinence, dysuria, hematuria, urinary retention, cystitis, hypothyroidism, hypercholesterolemia, dehydration, hypokalemia, hyperlipidemia, gout, bone pain, synovitis, mania, abdominal pain, fecal incontinence, neuritis, hallucinations, EEG changes, dysarthria, hyperesthesia, dystonic reaction, lymphocytosis, thrombocytopenia, leukopenia, phlebitis, priapism, psoriasis, furunculosis, hypoxia, hypoventilation, hemoptysis, blepharitis, iritis, exophthalmos, hyperacusis, hepatitis, flank pain, glycosuria, hyperglycemia, diabetes mellitus, hypocalcemia, hyperuricemia, myopathy, myasthenia, osteoporosis, confusion, amnesia, QT prolongation, hypertension, palpitations, chest pain (unspecified), dyskinesia, memory impairment, impulse control symptoms, hematoma, bleeding, platelet dysfunction, hyponatremia, galactorrhea, hyperprolactinemia, dyspnea, cataracts, jaundice, hypoglycemia, osteopenia, withdrawal, growth inhibition 

      Mild: insomnia, nausea, headache, asthenia, diarrhea, anorexia, drowsiness, anxiety, tremor, xerostomia, yawning, libido decrease, dyspepsia, pharyngitis, dizziness, hyperhidrosis, urticaria, rash, sinusitis, abnormal dreams, flushing, flatulence, vomiting, pruritus, weight loss, epistaxis, fever, hypersalivation, polydipsia, eructation, paranoia, vertigo, hypoesthesia, ecchymosis, syncope, breast enlargement, orgasm dysfunction, mastalgia, menorrhagia, libido increase, breast discharge, amenorrhea, leukorrhea, photosensitivity, alopecia, maculopapular rash, skin discoloration, acne vulgaris, malaise, hyperventilation, hiccups, mydriasis, xerophthalmia, polyuria, urinary urgency, nocturia, pelvic pain, arthralgia, muscle cramps, paresthesias, hyporeflexia, petechiae, purpura, pallor, hirsutism, seborrhea, parosmia, diplopia, appetite stimulation, weight gain, dysgeusia, emotional lability, hyperkinesis, agitation, hypothermia, chills, otalgia, tinnitus, increased urinary frequency, gynecomastia, influenza  


       Children, growth inhibition, suicidal ideation 

       Fluoxetine is approved for the treatment of depression in children 8 years of age and older, and for the treatment of obsessive-compulsive disorder (OCD) in children 7 years of age and older. The safety and effectiveness of fluoxetine in younger children have not been established. In October 2004, the FDA directed manufacturers of all antidepressants to include a boxed warning detailing the risk of suicide in pediatric patients. A causal role has been established for antidepressants in inducing suicidality in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n=4400) lasting up to 16 weeks in pediatric patients with major depressive disorder (MDD), obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants (SSRIs and others). The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment with SSRIs and other antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in children or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or at the time of dose increase or decrease. It is unknown if the suicidality risk in children and young adults extends to longer-term therapy (i.e., beyond several months). The possibility of a suicide attempt is inherent in patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder. All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment are considered at an increased risk for suicidal ideation or attempts, and should be closely monitored during treatment with fluoxetine. In patients who exhibit changes in symptoms, worsening of depression or emergent suicidality, a decision should be made to change or discontinue treatment. If discontinuing, medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management in order to reduce the risk of overdose. The potential for growth inhibition in pediatric patients should be monitored during SSRI therapy. Monitor height and weight periodically while the patient is receiving fluoxetine. Data are inadequate to determine whether the chronic use of SSRIs causes long-term growth inhibition; however, decreased weight gain has been observed in children and adolescents receiving fluoxetine. 



      According to the FDA:

      Discontinuation According to the FDA: Treatment

      Patients should be advised to take PROZAC exactly as prescribed, and to continue taking PROZAC as prescribed even after their symptoms improve. Patients should be advised that they should not alter their dosing regimen, or stop taking PROZAC without consulting their physician [see Warnings and Precautions (5.15)]. Patients should be advised to consult with their healthcare provider if their symptoms do not improve with PROZAC.

      If the decision has been made to discontinue treatment, medication should be tapered, as rapidly as is feasible, but with recognition that abrupt discontinuation can be associated with certain symptoms [see Warnings and Precautions


      *While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.

      *The statements/info on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.

      * Testimonial results may vary person to person.

      *The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized With Your physician to help you with your drug withdrawal process and with his or her consent and support throughout.

      *This program is not meant to cure or prevent any disease or illness.

      *Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support throughout the process. More..